Distinct cMET inhibitors uncover pharmacological heterogeneity in SHH medulloblastoma cell lines
Abstract The c-MET kinase signalling pathway is crucial in cerebellum development and has emerged as a potential therapeutic target for medulloblastoma treatment. Our study confirms that c-MET and its ligand HGF are highly expressed in the SHH medulloblastoma subgroup, with SHH-α and SHH-β subtypes...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer
2026-02-01
|
| Edice: | Discover Oncology |
| On-line přístup: | https://doi.org/10.1007/s12672-026-04717-7 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|